Report Company Directory
- Raymond James Morning Notes - ACRE, DK, ONEW, PSX, RC, TMUS, TRTX, VLO, XAN by Raymond James
- REITs | REITworld 2020 Conference Takeaways: Giving Thanks for Promising Vaccines; Tough Winter Ahead Before 2021 Recovery by Raymond James
- Portfolio Strategy | Morning Brew: October 14, 2020 by Raymond James
- Raymond James Morning Notes - AJX, IRET, JKHY, LZB, NRZ, NVDA, UMBF by Raymond James
- IRET | Downgrade to Market Perform; Rent Pressure Growing in DEN, MSP by Raymond James
- Raymond James Morning Notes - ABR, AJG, ANIP, CTRE, HRC, MMC, OHI, RUTH, UAA by Raymond James
- Real Estate | 2020 Midyear Update -- A Whole New World by Raymond James
- Portfolio Strategy | Morning Brew: July 15, 2020 by Raymond James
- Raymond James Morning Notes - HLT, HST, INN, PBR, PK, PROG, RHP, RLJ by Raymond James
- Housing | 2020 Housing Mid-Year Update Summary: 'Housing As Sanctuary' Resets Cycle by Raymond James
- ValuEngine Rating and Forecast Report for IRET by ValuEngine Inc
- ValuEngine Rating and Forecast Report for IRET by ValuEngine Inc
- ValuEngine Rating and Forecast Report for IRET by ValuEngine Inc
- ValuEngine Rating and Forecast Report for IRET by ValuEngine Inc
- Raymond James Morning Notes - AAPL, AUB, CUBE, ICPT, KSU, OHI, PEB, PTON, STT by Raymond James
- Institutional Equity Strategy | Raymond James Institutional Equity Strategy Weekly by Raymond James
- Raymond James Morning Notes - ETFC, IRET, ISRG, PFBC, SBNY, TSC, WTFC by Raymond James
- IRET | Initiating Coverage With Outperform, $83 Target by Raymond James
- InsiderInsights Daily Ratings Report: December 18, 2018 by InsiderInsights.com
- InsiderInsights Daily Ratings Report: December 20, 2018 by InsiderInsights.com
- SBCF | Deepens South Florida Presence With Legacy Bank of Florida Acquisition by Raymond James
- Raymond James Morning Notes - DXCM, FISV, FSLR, JNPR, MASI, MSM, NEO, PII, PPBI by Raymond James
- SBCF | 3Q20 First Look: Provision/Fee Strength Drives EPS Beat; PTPP Misses on PPP Fee Amortization by Raymond James
- Raymond James Morning Notes - AAP, APA, AR, BSM, CBSH, CNX, CVET, CXO, DCT, DVN, EOG, FANG, HSKA, HWC, IRDM, LPI, MNRL, PCAR, PLAY, RF, RRC, SBNY, SWN, TBK, VNOM, XEC by Raymond James
- CFB | 3Q20 Results Roughly In Line With Street Expectations; Announces $20 Million Share Buyback by Raymond James
- Raymond James Morning Notes - BR, EW, HZO, OSBC, PHM, SWKS, TSCO, UNP by Raymond James
- CFB | Reit. Market Perform Post 2Q20 PTPPI Beat; Reducing Estimates by Raymond James
- SBCF | 2Q20 First Look: Core EPS/PTPP Earnings Beat; Trends Favorable by Raymond James
- Raymond James Morning Notes - AMRC, EFSC, ISRG, LYFT, PCAR, UBER, VBIV by Raymond James
- SFNC | 2Q20 Follow-Up: Raising 2020/21 EPS; Maintain Outperform by Raymond James
- Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 by GlobeNewsWire
- Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting by GlobeNewsWire
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences by GlobeNewsWire
- Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer by GlobeNewsWire
- Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update by GlobeNewsWire
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences by GlobeNewsWire
- Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) by GlobeNewsWire
- Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares by GlobeNewsWire
- Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares by GlobeNewsWire
- Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers by GlobeNewsWire